We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Only a week after AstraZeneca worked up a deal to sell some Nexium and Vimovo rights for hundreds of millions of dollars, the company is back at it with an agreement that’ll generate $350 million in cash.